Evidence map›Paper›PMID 42761237›Full record

ReviewFrontiers in bioengineering and biotechnology2026

Industry-defined opportunities for advancing big data capabilities in biopharmaceutical manufacturing.

Roger Hart, Sandeep Kedia, Rachel Lanspa, Sarah Lichtner, Kelvin H Lee

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Roger HartThe National Institute for Innovation in Manufacturing Biopharmaceuticals, Newark, DE, United States.
Sandeep KediaThe National Institute for Innovation in Manufacturing Biopharmaceuticals, Newark, DE, United States.
Rachel LanspaNexight Group, Silver Spring, MD, United States.
Sarah LichtnerNexight Group, Silver Spring, MD, United States.
Kelvin H LeeThe National Institute for Innovation in Manufacturing Biopharmaceuticals, Newark, DE, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biopharmaceuticals are the originating products of biotechnology, an area of increased focus for strategic U.S. leadership. The discovery, development, and manufacturing of biopharmaceuticals create large amounts of data, which is then managed and preserved for business and regulatory purposes. In accordance with the resource-based view management framework, this data is a resource which, when combined with the right capabilities, is foundational to building a company's competitive market advantage. Big Data Capabilities to acquire, analyze, curate, store, and use data for targeted purposes across the entire biopharmaceutical manufacturing lifecycle are key to realizing business value from big data collections. This paper describes these capabilities in relation to recent advances in biopharmaceutical manufacturing and the benefits these capabilities can help realize. We argue that developing shared capabilities benefits both individual businesses, who can adopt and adapt them to establish their own strategy and competitive advantage, as well as the entire industry, which advances biopharmaceutical science through shared knowledge and collaboration. This paper was derived from extensive material collected from biopharmaceutical manufacturing industry subject matter experts gathered by the Big Data Program of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

Indexed as

big databiopharmaceutical manufacturingcapabilitymanufacturing lifecycleprocess improvementresource-based view

Identifiers

PMID42761237
PMCPMC13586689

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.